Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2546)
All Articles published online
|
Mar 1, 2004 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Jeng KS, Sheen IS, Wang YC, Gu SL, Chu CM, Shih SC, Wang PC, Chang WH, Wang HY. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: A prospective study. World J Gastroenterol 2004; 10(5): 643-648 [PMID: 14991930 DOI: 10.3748/wjg.v10.i5.643] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v10/i5/643.htm |
| Number | Citing Articles |
| 1 |
Matthias Pinter, Wolfgang Sieghart, Monika Schmid, Bernhard Dauser, Gerald Prager, Hans Peter Dienes, Michael Trauner, Markus Peck‐Radosavljevic. Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF‐A expression in hepatocellular carcinoma. United European Gastroenterology Journal 2013; 1(4): 265 doi: 10.1177/2050640613496605
|
| 2 |
Kimberly Terry, Mehmet Sitki Copur. Molecular Targeted Therapy of Hepatocellular Carcinoma. Journal of Cancer Therapy 2013; 4(02): 426 doi: 10.4236/jct.2013.42A052
|
| 3 |
Andrew X Zhu. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. Expert Opinion on Investigational Drugs 2010; 19(5): 663 doi: 10.1517/13543781003767426
|
| 4 |
Su Jin Lee, Ho Yeong Lim. Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists. Expert Opinion on Emerging Drugs 2017; 22(2): 191 doi: 10.1080/14728214.2017.1330886
|
| 5 |
SANG YOUN HWANG, KYU HEO, JOON SEOK KIM, JUNG WOO IM, SUN MI LEE, MONG CHO, DAE HWAN KANG, JEONG HEO, JUN WOO LEE, CHEOL WON CHOI, KWANGMO YANG. Emodin attenuates radioresistance induced by hypoxia in HepG2 cells via the enhancement of PARP1 cleavage and inhibition of JMJD2B. Oncology Reports 2015; 33(4): 1691 doi: 10.3892/or.2015.3744
|
| 6 |
Matthias Preusser, Stefan Wolfsberger, Christine Haberler, Helene Breitschopf, Thomas Czech, Irene Slavc, Adrian L. Harris, Till Acker, Herbert Budka, Johannes A. Hainfellner. Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathologica 2005; 109(2): 211 doi: 10.1007/s00401-004-0938-8
|
| 7 |
|
| 8 |
Andrew X. Zhu. Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?. The Oncologist 2006; 11(7): 790 doi: 10.1634/theoncologist.11-7-790
|
| 9 |
Ismail Labgaa, Augusto Villanueva, Olivier Dormond, Nicolas Demartines, Emmanuel Melloul. The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. Cancers 2021; 13(4): 659 doi: 10.3390/cancers13040659
|
| 10 |
Andrew X. Zhu. Systemic Treatment of Hepatocellular Carcinoma: Dawn of a New Era?. Annals of Surgical Oncology 2010; 17(5): 1247 doi: 10.1245/s10434-010-0975-6
|
| 11 |
Jun Muto, Ken Shirabe, Keishi Sugimachi, Yoshihiko Maehara. Review of angiogenesis in hepatocellular carcinoma. Hepatology Research 2015; 45(1): 1 doi: 10.1111/hepr.12310
|
| 12 |
Roberta Pang, Ronnie T.P. Poon. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Letters 2006; 242(2): 151 doi: 10.1016/j.canlet.2006.01.008
|
| 13 |
Kun‐Chun Chiang, Chun‐Nan Yeh, Miin‐Fu Chen, Tai C Chen. Hepatocellular carcinoma and vitamin D: A review. Journal of Gastroenterology and Hepatology 2011; 26(11): 1597 doi: 10.1111/j.1440-1746.2011.06892.x
|
| 14 |
Ahmed O. Kaseb, Amr Hanbali, Matthew Cotant, Manal M. Hassan, Ira Wollner, Philip A. Philip. Vascular endothelial growth factor in the management of hepatocellular carcinoma. Cancer 2009; 115(21): 4895 doi: 10.1002/cncr.24537
|
| 15 |
SHANSHAN SHI, CHENXING YUAN, KAIZAN ZHUANG, GUIKAI LIANG, ZHANGTING YAO, DUODUO WANG, QINJIE WENG, JI CAO, PEIHUA LUO, HONG ZHU, LING DING, SHENGLIN MA. Resistance of SMMC-7721 hepatoma cells to etoposide in hypoxia is reversed by VEGF inhibitor. Molecular Medicine Reports 2015; 11(5): 3842 doi: 10.3892/mmr.2015.3217
|
| 16 |
F. Meriggi, A. Zaniboni. Gemox: A Widely Useful Therapy Against Solid Tumors-Review and Personal Experience. Journal of Chemotherapy 2010; 22(5): 298 doi: 10.1179/joc.2010.22.5.298
|
| 17 |
Karen Mulder, Sheryl Koski, Andrew Scarfe, Quincy Chu, Karen King, Jennifer Spratlin. Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget 2010; 1(7): 515 doi: 10.18632/oncotarget.187
|
| 18 |
D. Germano, V. Tinessa, E. Barletta, L. Cannella, B. Daniele. Targeted Therapy for Advanced Hepatocellular Cancer in the Elderly: Focus on Sorafenib. Drugs & Aging 2013; 30(11): 887 doi: 10.1007/s40266-013-0124-6
|
| 19 |
Andrew X. Zhu. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2008; 112(2): 250 doi: 10.1002/cncr.23175
|
| 20 |
S J Schoenleber, D M Kurtz, J A Talwalkar, L R Roberts, G J Gores. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. British Journal of Cancer 2009; 100(9): 1385 doi: 10.1038/sj.bjc.6605017
|
| 21 |
Koji Miyahara, Kazuhiro Nouso, Takeshi Tomoda, Sayo Kobayashi, Hiroaki Hagihara, Kenji Kuwaki, Junichi Toshimori, Hideki Onishi, Fusao Ikeda, Yasuhiro Miyake, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Kazuhide Yamamoto. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2011; 26(11): 1604 doi: 10.1111/j.1440-1746.2011.06887.x
|
| 22 |
S.-Y. Gao, L. Tang, Y. Cui, X.-T. Li, X.-Y. Zhang, J. Shan, Y.-S. Sun, X.-P. Zhang. Tumor angiogenesis-related parameters in multi-phase enhanced CT correlated with outcomes of hepatocellular carcinoma patients after radical hepatectomy. European Journal of Surgical Oncology (EJSO) 2016; 42(4): 538 doi: 10.1016/j.ejso.2016.01.008
|
| 23 |
Satoshi Miuma, Tatsuki Ichikawa, Kazuhiko Arima, Shigeyuki Takeshita, Toru Muraoka, Toshihisa Matsuzaki, Masashi Ootani, Hidetaka Shibata, Motohisa Akiyama, Eisuke Ozawa, Hisamitsu Miyaaki, Naota Taura, Fuminao Takeshima, Kazuhiko Nakao. Branched‐chain amino acid deficiency stabilizes insulin‐induced vascular endothelial growth factor mRNA in hepatocellular carcinoma cells. Journal of Cellular Biochemistry 2012; 113(10): 3113 doi: 10.1002/jcb.24188
|
| 24 |
Eleni Liapi, Christos S. Georgiades, Kelvin Hong, Jean-Francois H. Geschwind. Interventional Oncology. 2008; : 202 doi: 10.1017/CBO9780511722226.018
|
| 25 |
Andrew X. Zhu. Molecularly Targeted Therapy for Advanced Hepatocellular Carcinoma in 2012: Current Status and Future Perspectives. Seminars in Oncology 2012; 39(4): 493 doi: 10.1053/j.seminoncol.2012.05.014
|
| 26 |
Andrew X. Zhu, Dan G. Duda, Dushyant V. Sahani, Rakesh K. Jain. HCC and angiogenesis: possible targets and future directions. Nature Reviews Clinical Oncology 2011; 8(5): 292 doi: 10.1038/nrclinonc.2011.30
|
| 27 |
Andrew X. Zhu. New agents on the horizon in hepatocellular carcinoma. Therapeutic Advances in Medical Oncology 2013; 5(1): 41 doi: 10.1177/1758834012458480
|
| 28 |
Andrew X. Zhu, Lawrence S. Blaszkowsky, David P. Ryan, Jeffrey W. Clark, Alona Muzikansky, Kerry Horgan, Susan Sheehan, Kelly E. Hale, Peter C. Enzinger, Pankaj Bhargava, Keith Stuart. Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology 2006; 24(12): 1898 doi: 10.1200/JCO.2005.04.9130
|
| 29 |
Po‐Lin Tseng, Ming‐Hong Tai, Chao‐Cheng Huang, Chih‐Chi Wang, Jui‐Wei Lin, Chao‐Hung Hung, Chien‐Hung Chen, Jing‐Houng Wang, Sheng‐Nan Lu, Chuan‐Mo Lee, Chi‐Sin Changchien, Tsung‐Hui Hu. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. Journal of Surgical Oncology 2008; 98(5): 349 doi: 10.1002/jso.21109
|
| 30 |
Andrew X. Zhu, Nagaraj S. Holalkere, Alona Muzikansky, Kerry Horgan, Dushyant V. Sahani. Early Antiangiogenic Activity of Bevacizumab Evaluated by Computed Tomography Perfusion Scan in Patients with Advanced Hepatocellular Carcinoma. The Oncologist 2008; 13(2): 120 doi: 10.1634/theoncologist.2007-0174
|
| 31 |
Andrew X Zhu. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?. Expert Review of Anticancer Therapy 2008; 8(4): 499 doi: 10.1586/14737140.8.4.499
|
| 32 |
Lorenzo Fornaro, Caterina Vivaldi, Chiara Caparello, Rodolfo Sacco, Virginia Rotella, Gianna Musettini, Sauro Luchi, Edi Editta Baldini, Alfredo Falcone, Gianluca Masi. Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. Future Oncology 2014; 10(2): 285 doi: 10.2217/fon.13.181
|
| 33 |
Antoine Hollebecque, David Malka, Charles Ferté, Michel Ducreux, Valérie Boige. Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons. European Journal of Cancer 2015; 51(3): 327 doi: 10.1016/j.ejca.2014.12.005
|
| 34 |
Anuradha Budhu, Junfang Ji, Xin Wei Wang. Hepatocellular Carcinoma. 2009; : 131 doi: 10.1007/978-1-60327-376-3_5
|
| 35 |
ZHONG-LIN ZHANG, JI-FA ZHANG, YU-FENG YUAN, YUE-MING HE, QUAN-YAN LIU, XIAO-WEN MAO, YONG-BIAO AI, ZHI-SU LIU. Suppression of angiogenesis and tumor growth in vitro and in vivo using an anti-angiopoietin-2 single-chain antibody. Experimental and Therapeutic Medicine 2014; 7(3): 543 doi: 10.3892/etm.2014.1476
|
| 36 |
Richard S. Finn. Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?. Clinical Cancer Research 2010; 16(2): 390 doi: 10.1158/1078-0432.CCR-09-2084
|
| 37 |
Benyamin Lukito, Ivet Suriapranata, Pendrianto Pendrianto, Ali Sulaiman, Irawan Yusuf, FX Budhianto Suhadi, George Mathew, Ferry Sandra. Vascular Endothelial Growth Factor Level as A Predictor of Hepatocellular Carcinoma in Liver Cirrhosis Patients. The Indonesian Biomedical Journal 2014; 6(3): 167 doi: 10.18585/inabj.v6i3.30
|
| 38 |
J. Stuart Salmon, A. Craig Lockhart, Jordan Berlin. Anti-Angiogenic Treatment of Gastrointestinal Malignancies. Cancer Investigation 2005; 23(8): 712 doi: 10.1080/07357900500360024
|
| 39 |
Chace Wilson, Nicholas W. Dias, Stefania Pancini, Vitor Mercadante, Fernando H. Biase. Delayed processing of blood samples impairs the accuracy of mRNA-based biomarkers. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-12178-5
|
| 40 |
Brian I. Carr. Hepatocellular carcinoma: Current management and future trends. Gastroenterology 2004; 127(5): S218 doi: 10.1053/j.gastro.2004.09.036
|
| 41 |
Perumal Vivekanandan, Om V Singh. High-dimensional biology to comprehend hepatocellular carcinoma. Expert Review of Proteomics 2008; 5(1): 45 doi: 10.1586/14789450.5.1.45
|
| 42 |
Ming‐Yen Hsieh, Zu‐Yau Lin, Wan‐Long Chuang. Serial serum VEGF‐A, angiopoietin‐2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization. The Kaohsiung Journal of Medical Sciences 2011; 27(8): 314 doi: 10.1016/j.kjms.2011.03.008
|
| 43 |
Christopher D. Mann, Christopher P. Neal, Giuseppe Garcea, Margaret M. Manson, Ashley R. Dennison, David P. Berry. Prognostic molecular markers in hepatocellular carcinoma: A systematic review. European Journal of Cancer 2007; 43(6): 979 doi: 10.1016/j.ejca.2007.01.004
|
| 44 |
Kuo-Shyang Jeng, Chi-Juei Jeng, Wen-Juei Jeng, I-Shyan Sheen, Shih-Yun Li, Ssu-Jung Lu, Chiung-Fang Chang. Tropism of liver epithelial cells toward hepatocellular carcinoma in vitro and in vivo with altering gene expression of cancer stem cells. The American Journal of Surgery 2018; 215(4): 735 doi: 10.1016/j.amjsurg.2017.11.041
|
| 45 |
Andrew X. Zhu, Charles S. Fuchs, Jeffrey W. Clark, Alona Muzikansky, Kerry Taylor, Susan Sheehan, Kayao Tam, Elizabeth Yung, Matthew H. Kulke, David P. Ryan. A Phase II Study of Epirubicin and Thalidomide in Unresectable or Metastatic Hepatocellular Carcinoma. The Oncologist 2005; 10(6): 392 doi: 10.1634/theoncologist.10-6-392
|
| 46 |
Geertu Deli, Can-Hao Jin, Rong Mu, Song Yang, Yue Liang, De Chen, Masatoshi Makuuchi. Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World Journal of Gastroenterology 2005; 11(7): 960-963 doi: 10.3748/wjg.v11.i7.960
|
| 47 |
Malin Sund, Michael Zeisberg, Raghu Kalluri. Endogenous Stimulators and Inhibitors of Angiogenesis in Gastrointestinal Cancers: Basic Science to Clinical Application. Gastroenterology 2005; 129(6): 2076 doi: 10.1053/j.gastro.2005.06.023
|
| 48 |
Richard S Finn, Andrew X Zhu. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Review of Anticancer Therapy 2009; 9(4): 503 doi: 10.1586/era.09.6
|